Who is sponsoring NCT07315191?

NCT07315191 is sponsored by Capital Institute of Pediatrics, China.

What drugs are being tested in NCT07315191?

Interventions in NCT07315191: ACEI / ARB+finerenone, ACEI/ARB.

What condition does NCT07315191 study?

NCT07315191 studies Henoch Schönlein Purpura Nephritis.

Is NCT07315191 still recruiting?

NCT07315191 is currently recruiting now. Last updated 7 January 2026.

Last reviewed 2026-01-07 · How we verify

NCT07315191: FICHSPN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Finerenone Therapy for Pediatric HSPN With Mild Proteinuria

Recruiting now Phase 4 Last updated 7 January 2026

What this trial tests

Phase 4 trial testing ACEI / ARB+finerenone in Henoch Schönlein Purpura Nephritis in 116 participants. Currently enrolling.

Timeline

13 June 2025

Primary endpoint
31 October 2027

30 April 2028

Quick facts

Lead sponsor	Capital Institute of Pediatrics, China
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	116
Start date	13 June 2025
Primary completion	31 October 2027
Estimated completion	30 April 2028
Sites	1 location across China

Drugs / interventions tested

ACEI / ARB+finerenone — full drug profile →
ACEI/ARB — full drug profile →

Conditions studied

Henoch Schönlein Purpura Nephritis — all drugs for Henoch Schönlein Purpura Nephritis →

Sponsor

Capital Institute of Pediatrics, China

Who can join

Adults 3 to 18, any sex, with Henoch Schönlein Purpura Nephritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease. Currently, the treatment for children with mild proteinuria HSPN mainly involves ACEI/ARB, but long-term use of these drugs can lead to an increase in aldosterone levels, affecting therapeutic efficacy. Finerenone can improve vascular endothelial cell dysfunction and renal tissue inflammation and fibrosis, and reduce urinary protein in patients with glomerular diseases. This study intends to conduct an exploratory randomized controlled clinical trial of finerenone in children with HSPN accompanied by a small amount of proteinuria to evaluate the efficacy and safety of finerenone treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07315191 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Institute of Pediatrics, China
Last refreshed: 7 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07315191.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing